International and seasoned board members for Switzerland

HAYA Therapeutics, developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), has appointed Brian C. Thomas to the position of Chairperson of the Board of Directors, bringing extensive experience in biotech research and development. Thomas is the Founder and CEO of gene-editing company Metagenomi. Prior to founding Metagenomi, he spent more than 20 years at the University of California, Berkeley, advancing the science of metagenomics to understand novel biochemistry – his scientific work has been cited over 17,000 times. He is also listed as an inventor on numerous patents in the field of gene editing.

Agile Wind Power, Marcel Pawlicek
Cleantech startup Agile Wind Power develops unique turbines with a much less impact on the immediate environment, making them suitable for captive power production for energy-intensive commercial and industrial consumers. During this year’s summer, the company installed the second turbine of a worldwide new wind turbine technology. In addition to testing and preparations for commissioning, the company has started work on the series turbines with a view to delivering them to the first operators in 2024.

To support its technology’s market entry., the company has appointed Marcel Pawlicek to its board, bringing many years of broad-based experience in the industry, a large network and broad expertise in international sales. Marcel Pawlicek accompanied the development of Burckhardt Compression in various functions. He worked as an engineer and in sales and later was part of the management buyout team and successfully took Burckhardt Compression public. For the last eleven years, he has led the company as CEO. Today he is on the board of directors of several companies and shares his knowledge of business development, management consulting, marketing and sales strategy. His conviction for Agile Wind Power’s solutions led him to his new role.

Muntagnard appoints former Kjus CEO to its board
As an up-and-coming fashion label from Graubünden, Muntagnard produces textile innovations with an uncompromising commitment to quality, design and sustainability. The 2018 founded company is established both in the B2C market as a premium label and in the B2B sector as more companies seek biodegradable corporate clothing. With the appointment of Nico Serena, former CEO of KJUS and current founder and CEO of AYCANE to the board of directors, Muntagnard gets an experienced member in the circular fashion industry. Nico has established himself in marketing textile innovations globally, and is now bringing his sales and textile expertise to the startup.

Kandou welcomes Tom Lacy
BasEd in Lausanne, Kandou is an innovative leader in high-speed, energy-efficient chip-to-chip link solutions that improve how the world connects and communicates. The startup has named Tom Lacey, former serial private and public company CEO to its board of directors. Lacey joins Kandou as it continues building on its success in developing differentiated semiconductor interconnect technology for large markets. He brings vast public and private company business development, M&A, governance, product development, technology/IP licensing, operations, international and leadership experience in both CEO and Board of Director roles.

Immunos Therapeutics appoints Joseph Leveque
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, welcomed Joseph Leveque. Leveque has over a decade of experience in the development of immuno-oncology therapeutics. He is currently President, Chief Medical Officer, and a Board Member of Medikine.

Prior to Medikine, he was Executive Vice President and Chief Medical Officer of Mirati Therapeutics (Nasdaq:MRTX), where he was responsible for the clinical development of their portfolio of selective KRAS inhibitors and other small molecules for cancer therapy. His previous roles include Chief Medical Officer (CMO) of Synthorx (acquired by Sanofi), a company focused on the application of synthetic biology in the discovery and development of cytokines, and CMO of ARMO Biosciences, an immuno-oncology company that was acquired by Eli Lilly. Earlier in his career, he was CMO of EMD Serono, the North American subsidiary of Merck KGaA, and Vice President and Head of US Medical Oncology at Bristol-Myers Squibb, where he was part of the team developing and commercializing the first generation of immuno-oncology therapeutics. He also held key medical leadership positions at Onyx Pharmaceuticals, Cephalon Oncology, and Amgen.

(Press release/RAN)
Photo: L-R: Brian C. Thomas, Nico Serena, Tom Lacey & Joseph Leveque